Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib (Q35214229)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

title

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

main subject

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author

Paolo Grassi

object named as

Paolo Grassi

series ordinal

1

0 references

Elena Verzoni

object named as

Elena Verzoni

series ordinal

2

0 references

Giuseppe Procopio

object named as

Giuseppe Procopio

series ordinal

6

0 references

Filippo de Braud

object named as

Filippo de Braud

series ordinal

5

0 references

Roberto Iacovelli

series ordinal

4

object named as

Roberto Iacovelli

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

author name string

Luca Porcu

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

publication date

1 April 2015

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

published in

Therapeutic advances in urology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

volume

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

page(s)

59-68

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

cites work

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

28 July 2018

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Distribution of metastatic sites in renal cell carcinoma: a population-based analysis.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4372524

retrieved

26 September 2018

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25829949

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/25829949

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1177/1756287215571809

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

PMC publication ID

4372524

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

PubMed publication ID

25829949

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25829949

retrieved

7 August 2017

ResearchGate publication ID

273491482

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35214229&oldid=1948602785"